loading page

Epstein Barr Virus in childhood and adolescent classical Hodgkin lymphoma in a French cohort of 301 patients
  • +10
  • Victor Pereira,
  • Sabah Boudjemaa,
  • Caroline Besson,
  • Thierry Leblanc,
  • Charlotte Rigaud,
  • Amaury Leruste,
  • Nathalie Garnier,
  • Anne Lambilliotte,
  • Mathieu Simonin,
  • Catherine Curtillet,
  • Jacinthe Bonneau-Lagacherie,
  • Aurore COULOMB L'HERMINE,
  • Judith Landman-Parker
Victor Pereira
Centre Hospitalier Universitaire de Besançon
Author Profile
Sabah Boudjemaa
Armand-Trousseau Childrens Hospital
Author Profile
Caroline Besson
Hospital Andre Mignot
Author Profile
Thierry Leblanc
Assistance Publique - Hôpitaux de Paris
Author Profile
Charlotte Rigaud
Gustave Roussy
Author Profile
Amaury Leruste
Curie Institute Hospital Group
Author Profile
Nathalie Garnier
Hospices Civils de Lyon
Author Profile
Anne Lambilliotte
Jeanne de Flandre Hospital
Author Profile
Mathieu Simonin
Armand-Trousseau Childrens Hospital
Author Profile
Catherine Curtillet
Hospital Timone
Author Profile
Jacinthe Bonneau-Lagacherie
University Hospital Centre Rennes
Author Profile
Aurore COULOMB L'HERMINE
Armand-Trousseau Childrens Hospital
Author Profile
Judith Landman-Parker
Hopital Armand-Trousseau
Author Profile

Abstract

To analyze the role of Epstein-Barr virus (EBV) in the biological and clinical characteristics of patients treated for classic Hodgkin lymphoma (cHL) in France. Bio-pathological data of 301 patients treated for a cHL in or according to the protocol of the EuroNet PHL-C1 trial between November 2008 and February 2013 were centrally reviewed. Median age at diagnosis was 14 [3-18] years and the F/M ratio 0.86, 0.47 before 10 years and 0.9 from 11 to 18. CHL subtypes were nodular sclerosis for 266/301 (88%) patients, mixed cellularity for 22/301 (7%), lymphocyte rich for 2/301 (1%), and 11/301 were unclassified. EBV expression in situ (EBV cHL) was observed for 68/301 (23%) patients, significantly associated with MC subtype and male gender, and there was a trend with age <10 years, it was particularly overrepresented in boys below 10 years: 15/23 (65%) vs 28/139 among other male patients (20%). Event-free and overall survival were equivalent between EBV and non-EBV cHL patients. EBV viral load was tested for 108/301 patients and detectable in 22/108 (22%) cases. A positive viral load was overrepresented in EBV cHL versus non-EBV cHL patients: 13/28 (46%) vs 9/80 (11%). Detailed semi-quantitative histological analysis showed a high number of B-cell residual follicles in EBV cHL and no significant association with CD 20 or PAX 5 immunostaining in tumoral cells relative to EBV-negative HL. Distribution of EBV cHL in children and adolescents is associated with young age and male gender, suggesting a specific physiopathology and may require a differential therapeutic approach.